Immunohistochemistry is widely used to support a pathology diagnosis of cervical adenocarcinoma despite the absence of a systematic review and meta-analysis of the published data. This systematic review and meta-analysis was performed to investigate the sensitivity and specificity of immunohistochemistry biomarkers in the tissue-based diagnosis of cervical adenocarcinoma histotypes compared with normal endocervix and benign glandular lesions. The systematic review and meta-analysis used a PICOT framework and QUADAS-2 to evaluate the quality of included studies. The literature search spanned 40 years and ended June 30, 2015. Abstracts of identified records were independently screened by 2 of the authors who then conducted a full-text review of selected articles. Sensitivity and specificity of immunohistochemistry expression in malignant glandular lesions of the cervix classified per WHO 2003 compared with 5 benign comparators (normal/benign endocervix, and benign endocervical, endometrioid, gastric, and mesonephric lesions) were calculated. Of 902 abstracts screened, 154 articles were selected for full review. Twenty-five articles with results for 36 biomarkers were included. The only biomarker with enough studies for a meta-analysis was p16 and the definition of positive p16 staining among them was variable. Nevertheless, any positive p16 expression was sensitive, ranging from 0.94 to 0.98 with narrow confidence intervals (CIs), for adenocarcinoma in situ (AIS) and mucinous adenocarcinomas in comparison with normal/benign endocervix and benign endocervical and endometrioid lesions. Specificity for AIS and mucinous adenocarcinomas was also high with narrow CIs compared with benign endocervical lesions. The specificity was high for AIS, 0.99 (0.24, 1.0), and mucinous adenocarcinoma, 0.95 (0.52, 1.0), compared with normal/benign endocervix but with wider CIs, and low with very wide CIs compared with benign endometrioid lesions: 0.31 (0.00, 0.99) and 0.34 (0.00, 0.99), respectively. Results from single studies showed that p16, p16/Ki67 dual stain, ProExC, CEA, ESA, HIK1083, Claudin 18, and ER loss in perilesional stromal cells were useful with high (Z0.75) sensitivity and specificity estimates in Z1 malignant versus benign comparisons. None of the biomarkers had highly useful sensitivity and
specificity estimates for AIS, mucinous adenocarcinomas, or minimal deviation adenocarcinoma/gastric adenocarcinoma compared with benign gastric or mesonephric lesions or for mesonephric carcinoma compared with normal/benign endocervix, benign endocervical, endometrial, or mesonephric lesions. Any expression of p16 supports a diagnosis of AIS and mucinous adenocarcinomas in comparison with normal/benign endocervix and benign endocervical lesions. The majority of studies did not separate mosaic/focal p16 staining from diffuse staining as a distinct pattern of p16 overexpression and this may have contributed to the poor performance of p16 in distinguishing AIS and mucinous adenocarcinomas from benign endometrioid lesions. Single studies support further investigation of 8 additional biomarkers that have highly useful sensitivity and specificity estimates for Z1 malignant glandular lesions compared with Z1 of the 5 benign comparators. Key Words: Meta-analysis-Systematic review-p16-Biomarker-Immunohistochemistry-AIS-Cervical adenocarcinoma-Diagnosis.
Between 10% and 25% of carcinomas of the uterine cervix are adenocarcinomas (1) . On the basis of the World Health Organization (WHO) 2003 classification of cervical tumors, there are 18 histotypes of primary, malignant glandular tumors (2) . Most are an endocervical type of mucinous adenocarcinoma, but rarer types such as minimal deviation adenocarcinoma (MDA) and mesonephric carcinoma also occur (1, 2) . Endocervical adenocarcinoma in situ (AIS) is considered the precursor lesion of endocervical-type, mucinous adenocarcinoma (1, 2) . Numerous benign glandular lesions are also described and can be broadly grouped as: (1) benign endocervical lesions comprised of cystic tunnel clusters, Nabothian cysts, and microglandular hyperplasia; (2) benign endometrioid lesions comprised of tuboendometrioid metaplasia and endometriosis; (3) benign gastric lesions comprised of noncystic tunnel clusters, pyloric gland metaplasia, and lobular endocervical glandular hyperplasia; and (4) benign mesonephric lesions comprised of mesonephric duct remnants and mesonephric hyperplasia (1) (2) (3) .
Immunohistochemistry (IHC) is widely relied on to support the histopathologic diagnosis of AIS and invasive adenocarcinoma, and their distinction from normal/benign endocervix and benign glandular lesions. Some of the most frequently utilized diagnostic biomarkers include p16, estrogen receptor (ER), polyclonal carcinoembryonic antigen (pCEA), and Vimentin (3) . There are many publications outlining the expression of these and a wide variety of other diagnostic IHC biomarkers in various malignant and benign glandular lesions of the cervix. However, uncertainty exists in regard to their diagnostic accuracy in the tissue-based diagnosis of glandular lesions of the uterine cervix. This systematic review and meta-analysis (SRMA) of the published literature was conducted to investigate the sensitivity and specificity of IHC biomarkers in the diagnosis of AIS and cervical adenocarcinomas in comparison with normal/benign endocervix and benign glandular lesions.
METHODS
The SRMA was designed using a PICOT (Population, Index test, Comparator test, Outcomes, Time interval) framework (4) . The Population consisted of AIS and primary invasive adenocarcinomas of the uterine cervix classified per WHO 2003 (2) . Gastric adenocarcinoma (GAS) is a cervical adenocarcinoma histotype included in the WHO 2014 classification, which was not included in the WHO 2003 classification (1, 2) . Any study of GAS identified in the literature review was included in the SRMA, and in accordance with the WHO 2014 classification, was combined with its low-grade variant MDA (2) . The Index test was IHC expression in tissue samples. The 5 normal-benign glandular Comparator tests consisted of normal/benign endocervix, and benign endocervical, endometrioid, gastric, and mesonephric lesions. The main Outcome was sensitivity and specificity of IHC expression. The Time Interval for the first literature search spanned January 1, 1975 to December 31, 2013, and 2 separately conducted update searches were concluded immediately before the analysis date of June 30, 2015 .
The literature search strategy and the inclusion and exclusion criteria are summarized in Table 1 . The abstracts of all publication records identified in the databases and other source searches were independently screened for study eligibility by 2 (S.L. and M.A.D.) of the authors. The screening results were compared by S.L. and any disagreements were resolved by a review of the abstract and a consensusbased discussion between both authors. The full-text articles of potential inclusions were independently read by the same 2 authors. Disagreements were resolved as before. Data for 22 attributes were extracted from the selected articles independently by the same 2 authors into a customized Excel (Microsoft Office; Microsoft, Redmond, WA) spreadsheet. The most relevant attributes were study design, IHC biomarker name, IHC scoring details, positive and negative IHC cut offs, malignant glandular histotype, case sample size, type of control, control sample size, true positives, false positives, true negatives, and false negatives. The extracted data were compared and disagreements were identified by S.L. and resolved as previously described. The final selection of included articles was independently evaluated for quality by 2 of the authors (S.R. and S.L.) using Quality Assessment of Diagnostic Accuracy version 2 (QUADAS-2) (5). Disagreements were resolved by consensus discussion.
Analysis
Malignant glandular tumors comprised the Population and were grouped as follows: (1) AIS, (2) mucinous adenocarcinoma that included superficially invasive adenocarcinoma, endocervical adenocarcinoma, intestinal adenocarcinoma, MDA/GAS, signet ring adenocarcinoma, and villoglandular adenocarcinoma as classified in WHO 2003, as well as mucinous adenocarcinoma or glandular carcinoma not otherwise specified, (3) endometrioid carcinoma, (4) serous and clear cell carcinoma, (5) adenosquamous carcinoma that included glassy cell carcinoma, and (6) mesonephric carcinoma. As MDA/GAS is now known to be a distinct histotype unrelated to highrisk human papillomavirus (hrHPV), it was also analyzed separately from the mucinous adenocarcinoma group (1, 3) . Sensitivity and specificity with 95% confidence intervals (CIs) for every antibody in every paired malignant-benign comparison were acquired directly from the published article or calculated from the raw data. Whenever possible, combined estimates from multiple individual studies were calculated using a bivariate mixed effects regression model [MetaAnalytical Integration of Diagnostic Accuracy Studies (MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies)] using Stata version 13.0 (2013, Stata Statistical Software: Release 13; StataCorp., College Station, TX) (6) . When the number of studies involved was too small to apply this model, the combined sensitivity and combined specificity estimates were calculated using an inverse variance weighted analysis. In some of these studies, the sensitivity or specificity was exactly equal to 1.0. In these studies, a 1-sided 97.5% CI was reported. For the MA, a random effects model was used to account for heterogeneity between study estimates. Heterogeneity was reported using Cochrane Heterogeneity Statistic Q and the quantity I 2 , which is defined as the percentage of total variation across the studies included in the MA attributable to heterogeneity.
RESULTS
There were 902 articles identified in the first search and 154 were selected for a full review and data extraction. Details of the additional articles and inclusions and exclusions are shown in Figure 1 comprised of 25 articles with results for 36 unique biomarkers .
In general, the values of I 2 were high (ranging from 83% to 98%) for the estimates of specificity, indicating that most of the variability was due to the effect of sample size and the variability between studies. However, for the sensitivity estimates, the values of I 2 were much lower (ranging from 0% to 57%) due to the effect of fewer cases, but in all estimates the CIs were extremely wide making the interpretation of I 2 very difficult. CIs of all estimates were evaluated and interpreted as conclusive when the lower limit was >0.5 and not conclusive when it was r0.5. Estimates were then categorized as useful when they were >0.5 and the CIs were conclusive and not useful when the estimate and upper limit of the CIs were r0.5.
p16 Expression
The most frequently studied biomarker was p16 and a MA was possible on data extracted from 8 studies for AIS and mucinous adenocarcinoma and 3 of the 5 benign comparators (normal/benign endocervix, and benign endocervical and endometrioid lesions) (7) (8) (9) (10) (11) (12) (13) (14) . Variability between the 8 studies in regard to the p16 clone and definition of positive and negative p16 expression occurred (Table 2) . Five different p16 clones were used in 6 of the studies and 2 did not specify the clone used. Definitions of positive p16 expression were also variable. Only 1 study required diffuse expression in >80% of the cells and one other required strong staining without quantifying the extent (7, 14) . In the remaining studies, positive staining was focal and/or diffuse expression of any intensity and extent was sometimes quantitated, but mostly not. Estimates of combined p16 sensitivity were Z0.94 with conclusive CIs for AIS and mucinous adenocarcinoma for the 3 benign comparators (Fig. 2) . Combined p16 specificity estimates for both tumor types in comparison with normal/benign endocervix and benign endocervical lesions were Z0.93 and conclusive except for AIS compared with normal/benign endocervix. Notably, in the comparisons of AIS and mucinous adenocarcinomas to benign endometrioid lesions, the specificity estimates were 0.31 and 0.34, respectively, but the wide CIs containing 0.5 were not conclusive.
As there was only 1 study with benign gastric lesions as the control, a MA was not possible for this comparator (9) . In that study, p16 expression in 72 AIS and 69 mucinous adenocarcinomas was compared with 41 benign gastric lesions. The sensitivity estimates for AIS and mucinous adenocarcinoma were useful: 0.90 (0.81, 0.96) and 0.93 (0.83, 0.98), respectively. However, the specificity estimate of 0.63 Izadi-Mood (2014) 13 Lin (2005) 12 Volgareva (2004) 11 Tringler (2004) 10 Mikami (2004) 9 Murphy (2003) (0.47, 0.79) for both tumor types was not conclusive. The study also compared p16 expression in MDA/ GAS, adenosquamous carcinoma, and cervical endometrioid carcinoma to normal/benign endocervix and benign endocervical, endometrioid, and gastric lesions (Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/IJGP/A46). For MDA/GAS compared with all 4 comparators, the sensitivity estimates were between 0.12 and 0.30 and not useful. The specificity estimates, however, were useful and between 0.63 and 1.00, except for the comparison with benign gastric lesions that had a CI containing 0.5 (0.47, 0.79). For the comparison of endometrioid carcinoma to benign endometrioid lesions, the sensitivity and specificity estimates were useful and 1.00 (0.83, 1.00) and 0.95 (0.83, 0.89), respectively. For the remaining comparisons, either the sensitivity or the specificity estimate was useful, but the corresponding estimate was either not conclusive or not useful.
Biomarker Expression Other Than p16
The literature on the IHC expression of biomarkers other than p16 in AIS, mucinous adenocarcinomas, MDA/GAS, and mesonephric carcinomas compared with the 5 benign comparators consisted mostly of individual studies. Expression was evaluated in Z1 biomarkers using variable numbers of cases and controls. The biomarkers are listed in the accompanying glossary and the evaluations are summarized as follows. In the comparison of AIS, mucinous adenocarcinomas, and MDA/GAS to any Z1 of the 5 comparators, 16, 30, and 18 different biomarkers, respectively, were evaluated. In the comparison of mesonephric carcinoma to benign endocervical, endometrioid, and mesonephric lesions, 2 different biomarkers were evaluated.
Biomarkers with both the sensitivity and specificity estimates interpreted as useful are detailed in Table 3 . One or more of 7 biomarkers (dual p16/Ki67, ProExC, ESA, CEA, Claudin 18, ER, and HIK1083) were useful in the comparison of AIS, mucinous adenocarcinoma, and MDA/GAS with normal/benign endocervix and benign endocervical and endometrioid lesions (14) (15) (16) (17) (18) . No biomarkers were useful in any comparisons with benign gastric or mesonephric lesions. Dual p16/Ki67 expression was useful for both AIS and mucinous adenocarcinoma compared with normal/benign endocervix and benign endocervical and endometrioid lesions (15) . ProExC was the only other biomarker useful for AIS in comparison with normal/benign endocervix (16) . ESA (17) and CEA (18) were useful for mucinous adenocarcinoma compared with normal/benign endocervix. CEA (18) , Claudin 18 (14) , and loss of ER expression in the lesional nuclei (14) were useful for MDA/GAS compared with normal/benign endocervix, and HIK1083 (14) was useful for MDA/GAS compared with benign endocervical and endometrioid lesions.
Biomarkers with either the sensitivity or specificity estimate interpreted as useful in comparisons of malignant glandular lesions with normal/benign endocervix, and benign endocervical, endometrioid, gastric, and mesonephric lesions are detailed in Supplemental Table 2 (Supplemental Digital Content 2, http://links.lww.com/IJGP/A47). Comparisons with normal/benign endocervix are summarized as follows. In the AIS comparisons, 2 biomarkers (pRB, CA-IX) had useful sensitivity estimates of 0.91 and 0.96, respectively, and 9 (ESA, CEA, pCEA, HIK1083, p53, MUC2, MUC6, Chromogranin, and CD10) had useful specificity estimates ranging from 0.95 to 1.00 (9, 10, (18) (19) (20) . In the mucinous adenocarcinoma comparisons, 5 biomarkers (pCEA, PHGDH, MUC5AC, Ubiquitin, and CD44v3) had useful sensitivity estimates ranging from 0.67 to 1.00, and 11 (HIK1083, Claudin 18, loss of ER in lesional nuclei, MUC6, MUC2, Chromogranin, CD10, CDX2, Vimentin loss, L1 capsid, and Telomerase) had useful specificity estimates ranging from 0.77 to 1.00 (9, 13, 14, (20) (21) (22) (23) (24) . In the MDA/GAS comparisons, 1 biomarker (pCEA) had a useful sensitivity estimate of 1.00, and 5 (HIK1083, MUC6, MUC2, Chromogranin, CD10, and CDX2) had useful specificity estimates ranging from 0.90 to 1.00 (9, 14, 20) .
Comparisons with benign endocervical lesions are summarized as follows. In the AIS comparisons, 1 biomarker (pRB) had a useful sensitivity estimate of 0.91 and 5 (MUC6, HIK1083, CD10, Chromogranin, and MUC2) had useful specificity estimates equal to 1.00 (9, 10, 14, 25) . In the mucinous adenocarcinomas comparisons, 1 biomarker (a-SMA expression in perilesional stromal cells) had a useful sensitivity estimate of 1.00 and 6 (MUC6, HIK1083, CD10, Chromogranin, MUC2, and Calretinin) had useful specificity estimates ranging from 0.94 to 1.00 (9, 14, 25, 26) . In the MDA/ GAS comparisons, 2 biomarkers (pCEA, and a-SMA expression in perilesional stromal cells) had useful sensitivity estimates equal to 1.00 and 5 (MUC6, CD10, Chromogranin, MUC2, and Calretinin) had useful specificity estimates ranging from 0.94 to 1.00 (9, 14, 20, 25, 26) . In the mesonephric carcinoma comparisons, 2 biomarkers (CD10 and pRB) were tested and both yielded only useful specificity estimates of 0.90 and 1.00, respectively (9, 25) . Comparisons with benign endometrioid lesions are summarized as follows. In the AIS comparisons, 5 biomarkers (HIK1083, Chromogranin, MUC6, MUC2, and CD10) had useful specificity estimates equal to 1.00 (9, 14) . In the mucinous adenocarcinomas comparison, the same 5 biomarkers plus Calretinin had useful specificity estimates of 1.00. In the MDA/GAS comparisons, 5 biomarkers (MUC6, MUC2, CD10, Chromogranin, and Calretinin) had useful specificity estimates equal to 1.00 (9, 14, 25) . In the mesonephric carcinoma comparisons, the 2 biomarkers (CD10 and Calretinin) tested yielded useful specificity estimates of 0.95 and 1.00, respectively (9, 25) .
Comparisons with benign gastric lesions are summarized as follows. In the AIS comparisons, 3 biomarkers (CD10, MUC2, and ER loss in perilesional stromal cells) had useful specificity estimates ranging from 0.90 to 1.00 (9, 25, 26) . In the mucinous adenocarcinoma comparisons, 2 biomarkers (a-SMA expression in perilesional stromal cells and CA-IX) had useful sensitivity estimates equal to 1.00 and 3 (CD10, MUC2, and ER loss in perilesional stromal cells) had useful specificity estimates ranging from 0.90 to 1.00 (9, (25) (26) (27) . In the MDA/GAS comparisons, 4 biomarkers (a-SMA expression in perilesional stromal cells, pCEA, HIK1083, and CA-IX) had useful sensitivity estimates ranging from 0.75 to 1.00 and 3 (CD10, MUC2, and ER loss in perilesional stromal cells) had useful specificity estimates ranging from 0.90 to 1.00 (9, 14, 20, (25) (26) (27) .
Comparisons of biomarker expression other than Calretinin in malignant glandular lesions in comparison with benign mesonephric lesions have not been reported. When mucinous adenocarcinoma, MDA/ GAS, and mesonephric carcinoma were compared with benign mesonephric lesions, Calretinin had a useful specificity estimate of 0.92 (25) .
Biomarkers with sensitivity and specificity estimates interpreted as not conclusive or not useful are detailed in Supplementary Table 3 (Supplemental Digital Content 3, http://links.lww.com/IJGP/A48). In summary, any Z1 of 20 biomarkers (p53, MUC5AC, pRB, Beclin1, LC3B, Notch1, Notch2, Keratin Sulphate, Pax2, CD44s, E-Cadherin, pCEA, a-SMA, ER, HIK1083, MUC6, Chromogranin, CA-IX, CD10, and Calretinin) were tested in Z1 malignant versus benign comparisons (9, 10, 14, 20, 23, (25) (26) (27) (28) (29) (30) (31) . Some biomarkers, for example, pCEA in the comparison of mucinous adenocarcinomas with benign endocervical lesions had a sensitivity >0.5 (0.71), but the estimate was not conclusive because of the wide CIs that contained the value 0.5 (0.29, 0.96) (20) . The wide CIs were likely related to the small sample size and inappropriate casecontrol ratio of 7 cases and 2 controls. Other biomarkers, such as PAX2 in the comparison of AIS with benign endometrioid lesions, where both the sensitivity and/or specificity estimate and upper limit of the CI were both o 0.5 and the sample size and ratio of cases to controls was appropriate, are unlikely to be useful in this setting and likely not worthy of further study (31) . No biomarker evaluated in this SRMA could be categorized as not useful in every malignant versus benign comparison. PAX 2 came close but expression in mesonephric carcinoma was not tested (31) .
DISCUSSION
On the basis of this SRMA, biomarkers with useful and highly (Z0.75) sensitive and specific estimates include p16, dual p16/Ki67, ProExC, CEA, ESA, ER loss in perilesional stromal nuclei, Claudin 18, and HIK1083 (Table 4) . The meta-analysis of multiple studies supports p16 expression in the diagnosis of AIS compared with benign endocervical lesions, and in mucinous adenocarcinomas compared with normal/benign endocervix and benign endocervical lesions. The systematic review of single studies supports further investigation of 8 biomarkers in select malignant versus benign comparisons as follows: p16 expression in the diagnosis of cervical endometrioid carcinoma in comparison with benign endometrioid lesions; dual p16/Ki67 in the diagnosis of AIS and mucinous adenocarcinomas in comparison with normal/benign endocervix, and benign endocervical and endometrioid lesions; CEA and ESA expression in the diagnosis of mucinous adenocarcinomas compared with normal/benign endocervical lesions; CEA and Claudin 18 expression, and ER loss in lesional nuclei in the diagnosis of MDA/GAS in comparison with normal/benign endocervix; and expression of HIK1083 in MDA/GAS in comparison with benign endocervical and endometrioid lesions. This is the first SRMA of the published literature on tissue-based immunohistochemical biomarker accuracy in the diagnosis of malignant glandular lesions of the uterine cervix. On the basis of the results of the meta-analysis, p16 emerged as the only biomarker for which there was sufficient evidence to support its use as a sensitive and specific diagnostic marker in select scenarios. This was not unexpected given the etiological role of the HPV in the genesis of most malignant glandular lesions of the uterine cervix. HPV is present in 94% of AIS, 85% of adenosquamous carcinomas, and 76% of cervical adenocarcinomas (all histotypes) (32) . When divided by histotype, HPV is most commonly associated with cervical adenocarcinoma, usual type (90%) and is less common in clear cell carcinoma (27%), serous carcinoma (30%), and endometrioid adenocarcinoma (13%) (32) . Multiple recent studies on MDA/GAS have confirmed that this subtype is unrelated to HPV (32) (33) (34) (35) . In relation to HPV, p16 overexpression is due to the viral protein E7 competing with the transcription factor E2F for its pRB-binding site.
Loss of the function of pRB leads to an upregulation of p16 through a feedback loop (36) . Overexpression of p16 can also occur in malignancies unassociated with HPV (37) . Any type of mutation/alteration to normal cellular function that interferes with or removes the function of pRB will result in elevated levels of p16 (37) . In addition, p16 can also be overexpressed in benign lesions as a marker of cellular senescence (37) . High sensitivity and specificity of p16 IHC occurred despite the lack of a standardized and consistently applied definition of positive and negative expression, and the use of several different p16 antibody clones. Most publications included in the p16 meta-analysis considered any p16 expression of any intensity to be a positive result. Only 1 paper defined positive p16 expression as strong nuclear and/or cytoplasmic staining (7) and only 1 defined this as diffuse strong staining in >80% of cells (14) . In addition, at least 5 different p16 clones were used. Two articles used the same clone (E6H4) (11, 12) and 2 articles did not list which specific clone was used (8, 14) (Table 2 ). These inconsistencies affect the heterogeneity or variance between the studies. In particular, for the AIS versus benign/normal endocervix comparison, 1 article (7) had a different definition of positive p16 expression than the other 2 (9,10). This article was also included in the mucinous adenocarcinoma versus normal/ benign endocervix comparison, but was 1 of 7 studies rather than 1 of 3.
Consistency in the use of a standardized definition of expression might have supported a broader application of p16 as a diagnostic marker. The specificity of p16 in the comparison with AIS and mucinous adenocarcinoma with benign endometrioid lesions had low specificities and wide CIs, which included a lower limit of 0.00. The lack of precision in the definition of positive p16 expression, limitations in the study design, and misclassification of the mucinous adenocarcinoma category all likely contributed to these results. Benign endometrioid lesions tend to have a mosaic or patchy p16 expression reflecting the admixture of ciliated and intercalated types of cells seen in this lesion (38) . In the articles included in this meta-analysis, focal p16 expression was seen in 70% of benign endometrioid lesions and all 3 articles included in the benign endometrioid lesions comparison defined positive p16 expression essentially as any staining (8) (9) (10) . Therefore, the low specificity was likely due to the low threshold for positive expression. The relatively small number of controls relative to cases, which was nearly inverse of the recommended 2:1 ratio, likely contributed to the wide CIs. Furthermore, the inadvertent inclusion of any of the HPV-negative cervical adenocarcinomas, such as MDA/GAS that show only focal p16 expression in a smaller proportion of cases (30%) (9, 14) , among the mucinous adenocarcinomas would also impact the specificity estimates. GAS is a newly defined histotype of cervical adenocarcinoma (MDA represents a welldifferentiated form of GAS), and would likely have been included in the mucinous adenocarcinoma group in older literature. MDA/GAS arises through a different carcinogenetic, HPV-unrelated pathway and does not show the same high-level expression of p16 as HPV-related cervical adenocarcinomas (32) (33) (34) (35) . Unlike the standardized definition of positive p16 expression in the HPV-associated cervical squamous lesions of high-grade squamous intraepithelial lesions as ''block-positive staining,'' and squamous carcinomas as ''strong diffuse nuclear and/or cytoplasmic staining,'' none exist for AIS and invasive adenocarcinomas (39) . Our results highlight the need for such a standardized definition and one which parallels the definition for HPV-associated cervical squamous lesions would be appropriate. We propose that continuous diffuse and strong nuclear and/or cytoplasmic staining proportionate to the area of the AIS and involving >90% of the adenocarcinoma are reasonable working definitions.
The systematic review identified p16 and dual p16/ Ki67, ProExC, CEA, ESA, ER loss in lesional nuclei, Claudin 18, and HIK1083 as diagnostic markers with highly useful sensitivity and specificity estimates in the select malignant versus benign comparisons detailed in Table 4 . However, for each of these biomarkers, estimates have not been published and likely not determined for all malignant lesions versus all 5 benign comparators, and this limits their application as a universal diagnostic marker. For example, ProExC expression was only investigated in AIS versus normal/ benign endocervix, when it probably has utility in other malignant versus benign comparisons (19) . Dual p16/ Ki67 expression is the most studied but has not been compared with the uncommon benign gastric and mesonephric lesions, nor has expression been studied in the relatively rare MDA/GAS. CEA, ESA, Claudin 18, and ER loss in lesional nuclei have not been evaluated in any comparisons of malignant glandular lesions with benign endocervical, endometrioid, gastric, or mesonephric lesions. Claudin 18 and ER loss in lesional nuclei have not been evaluated in AIS, and HIK1083 expression has not been evaluated in comparisons with benign mesonephric lesions. As the highly useful estimates are based on a single study and diagnostic performance has not been evaluated for every malignant versus benign comparison, additional study of this group of biomarkers is needed.
Several other biomarkers had useful sensitivity or specificity estimates, but not both in a number of malignant versus benign comparisons as detailed in Supplementary Tables 1 (Supplemental Digital Content 1, http://links.lww.com/IJGP/A46) and 2 (Supplemental Digital Content 2, http://links.lww.com/IJGP/ A47). Others, which are detailed in Supplementary  Table 3 (Supplemental Digital Content 3, http://links. lww.com/IJGP/A48), had sensitivity and specificity estimates that were not conclusive or useful in some comparisons. However, most of the data relating to these other biomarkers stemmed from small descriptive studies or discovery research and were not powered or designed to conduct a formal accuracy analysis, which likely compromised the estimates. This is reflected in the wide CIs of estimates >0.5, which contained the value 0.5. No biomarker out of the total of 36 could be categorized as not useful in every malignant versus benign comparison and this was mainly due to incomplete investigation. PAX2 came close but expression of PAX2 in mesonephric carcinoma was not tested. Thus, the systematic review supports further study of some of these biomarkers but with larger sample sizes and appropriate malignant/benign comparator ratios to clarify their diagnostic role.
The Cochrane database includes SRMAs on a variety of clinical topics but rarely on pathology and IHC topics (http://www.cochranelibrary.com/co chrane-database-of-systematic-reviews).
Immunoquery is an example of an online database resource that provides lists of IHC biomarkers in various pathologic conditions by descending prevalence or sometimes by sensitivity and specificity (http:// www.immunoquery.com). This resource and others like it are frequently used for diagnostic purposes by pathologists although their breadth, specificity, and interpretative value are not the same as an SRMA. The importance of an SRMA of IHC expression is incontestable given the value of the data in guiding a laboratories menu of diagnostic IHC antibodies and the pathologists' selection of a panel of antibodies. As the timing of this study shows, an SRMA as a timed publication is very challenging due to the large volume of published literature and the everchanging landscape of new information. Twice the literature was updated for the review and even with that, the closing date of the last review will be >12 months out of date by the time the results of the SRMA are published. We acknowledge this weakness and are exploring other ways to keep these data current. Our goal is to maintain the database and to update it periodically so as to continue clarifying the tissue-based IHC biomarker accuracy of malignant glandular lesions of the uterine cervix. Ongoing analysis of the SRMA data for future publication includes comparisons of biomarker expression in AIS with adenocarcinoma histotypes broadly categorized into those that are HPV related and those that are not, and comparisons of expression among the different adenocarcinoma histotypes.
